NCCN Request for Proposals (RFP): Preclinical Studies of Mirvetuximab Soravtansine for Selected Solid Tumors
The National Comprehensive Cancer Network (NCCN) has received a research grant from ImmunoGen under a Research Agreement dated as of March 6, 2015 (the “Research Agreement”) to support NCCN Member Institution faculty for the performance of preclinical studies with mirvetuximab soravtansine, previously known as IMGN853, in lung, breast, mesothelioma, endometrial, ovarian and gastric cancers. NCCN will serve as the funding organization for these grants that are available only to NCCN investigators. The following details the objectives, process and requirements of this RFP, which shall be
Investigators are asked to submit RFPs detailing proposed research projects. The overall aim of this RFP is to develop innovative studies of mirvetuximab soravtansine in lung, breast, mesothelioma, endometrial, ovarian and gastric cancers. Collaborative studies between NCCN Member Institutions are encouraged.
Deadline for RFPs: By 5:00 PM EDT, Monday, October 26, 2015.
For additional information, please contact Doreen Walker, Administrative Assistant, Oncology Research Program, at (215) 690-0565 or via email at Walker@nccn.org.
Tina Brozman Foundation 2015 Ovarian Cancer Research Pilot
To provide funding for a pilot project in ovarian cancer prevention and early detection, which would ultimately lead to national peer-reviewed grants.
The research proposal should not exceed three (3) pages, single-spaced (12 point font), with a description of aims, procedures and methods, background, and preliminary data if any. Include a timeline for the proposed research. References may exceed the 5-page limit. The application should clearly state how the research relates to ovarian cancer prevention and early detection. Applications that do not conform to the intent of this grant program will not be reviewed.
SUBMISSION: One PDF file of the complete application should be emailed to Donna Cropley (firstname.lastname@example.org) by the deadline. Incomplete applications or those received after the deadline will not be considered. For Additional Information: Please contact Yong.Zhu@yale.edu
Application Deadline: Friday, October 30, 2015
- Project Description, including an evaluation plan
- Budget Justification
Melanoma Research Alliance Grants
The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for high-impact translational research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment. This cycle, proposals will be accepted for Team Science Awards, Young Investigator Awards, Academic-Industry Partnership Awards (for Established Investigators), and Special Opportunity Awards. Team Science Letter of Intent Due: October 12, 2015 Young Investigator Award and Academic-Industry Partnership
November 16, 2015